News >

Expert Highlights Game-Changing Therapies for Acute Leukemia

Caroline Seymour
Published: Monday, Mar 05, 2018

William Donnellan, MD

William Donnellan, MD
While 2017 was a milestone year for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), where a combined 7 agents were approved by the FDA, the research is far from complete, as trials are exploring combinations and novel therapies.

 on Hematologic Malignancies, Donnellan, investigator of hematologic malignancies at Sarah Cannon Research Institute and Tennessee Oncology, discussed recent FDA approvals for the treatment of patients with AML and ALL, and highlighted emerging agents in the pipeline.

OncLive: Please discuss the 2017 FDA approvals in the field of acute leukemia?

Donnellan: There were many approvals that started in April with the approval of the FLT3 inhibitor midostaurin (Rydapt). It was approved based on the RATIFY study that showed a significant improvement in overall survival (OS) in patients with FLT3-ITD– and FLT3-TKD–mutated AML in combination with high-dose induction chemotherapy. Now, it’s really the standard of care around the country for patients with newly diagnosed AML who are receiving induction chemotherapy with anthracycline and cytarabine to add midostaurin and in combination with consolidation. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication